Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Enhancing self-esteem in people with multiple sclerosis using the Lexical Association Technique

Official title: Améliorer l'Estime de Soi Des Patients Atteints de sclérose en Plaques : Test d'efficacité de la Technique d'Association Lexicale

Run by University Hospital, Grenoble · NCT07064291 · Data updated 2026-11-12

This trial tests whether the Lexical Association Technique can improve well-being and quality of life for adults with recent MS diagnoses compared with a placebo-like control.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment160 (estimated)
SponsorUniversity Hospital, Grenoble
Academic / other
Locations1 site (Grenoble)
StatusRecruiting
StartedJanuary 28, 2026
Main results expectedJuly 27, 2027
Study endsJuly 27, 2027
Registry record updatedOctober 2, 2026
Trial IDNCT07064291 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with relapsing-remitting or secondary progressive MS diagnosed within the last 1–5 years, native French speakers, and with home computer and internet access on first- or second-line oral therapy.

Probably not a fit

Patients without access to a computer or internet, non-French speakers, or those outside the 1–5 year onset window may obtain little or no benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial compares the Lexical Association Technique (LAT) to an active control in adults with relapsing-remitting or secondary progressive MS diagnosed within the past 1–5 years. Participants complete at-home visualization exercises and fill out validated questionnaires on self-esteem, stress, anxiety, depression, quality of life, and adjustment to illness across multiple study points. The study uses computer-based intervention delivery and assesses immediate and short-term effects, with follow-up 14 days after the intervention. Enrollment requires native French speakers with at-home internet access, on first- or second-line oral MS therapy. Primary goals are to see if LAT increases well-being more than the control and whether it reduces psychological distress and improves quality of life.

Why it matters

Potential benefit: If successful, LAT could provide a non-pharmacologic option to boost self-esteem and overall well-being in people with MS.

How similar studies have gone: Prior work suggests psychosocial approaches can improve quality of life and well-being in MS, but the specific LAT approach is novel in this context.

Who can join: the full rules

Show full inclusion / exclusion criteria
INCLUSION CRITERIA

* Native French speaker
* Access to a computer and internet connection at home
* Diagnosis of multiple sclerosis according to the revised criteria of Thompson et al. (2018), either relapsing-remitting or secondary progressive form, between 1 and 5 years since disease onset (RRMS or SPMS entry phase)
* Currently receiving first- or second-line oral treatment (e.g., Teriflunomide, Dimethylfumarate, Fingolimod, Cladribine)
* Adult participants (age ≥ 18)

NON-INCLUSION CRITERIA

* Participant currently excluded from another study
* Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code (CSP), i.e., legally protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, individuals under psychiatric care under Articles L.3212-1 and L.3213-1 not falling under Article L.1121-8, individuals admitted to healthcare or social institutions for reasons other than research, minors, individuals under legal protection or unable to provide informed consent
* Staff members with a hierarchical link to the principal investigator

SECONDARY EXCLUSION CRITERIA

* Participants not presenting with low self-esteem, i.e., score \>26 on the Self-Esteem Scale (EES; Vallières \& Vallerand, 1990)
* Major life event significantly affecting well-being in the two weeks prior to study inclusion (e.g., bereavement, separation, childbirth, etc.)
* Initiation of psychological, psychiatric, or pharmacological treatment (anxiolytics, antidepressants) within one month prior to study start

Where it's running

  • CHU Grenoble Alpes
    Grenoble, France
    Recruiting

Study contacts

  • Principal investigator: Mathieu VAILLANT — CHU Grenoble Alpes, France

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.